Ceritinib in ALK-rearranged non-small-cell lung cancer.

By A. Shaw, J. Engelman. New England Journal of Medicine, 2014

659 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3c2f306ef347e00dc7c80290af26d8557d808bff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Nicolas Stransky
2. Ethan G. Cerami

In Oncology

1. Christoph Lengauer
2. Nicolas Stransky
3. S. Schalm
4. Ethan G. Cerami
5. Joseph L. Kim

In Pulmonary and Respiratory Medicine

1. Christoph Lengauer
2. Nicolas Stransky
3. S. Schalm
4. Ethan G. Cerami
5. Joseph L. Kim

Citations in the corpus

• The landscape of kinase fusions in cancer (2014, methodology): “Manual review was facilitated by the fact that passenger fusions could mainly be linked to the following: (1) the absence of a fusion protein coding sequence that was in-frame; (2) the kinase domain was absent or truncated from the predicted protein sequence; or (3) the kinase was found to be fused ”
• Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. (2016, neutral): “2 Range 22-79 22-79 Sex Male 61 (44) 54 (44) Female 77 (56) 68 (56) Ethnicity White 93 (67) 80 (66) Asian 36 (26) 33 (27) Other 9 (7) 9 (7) Smoking status Never smoker 96 (70) 87 (71) Former smoker 39 (28) 32 (26) Current smoker 3 (2) 3 (3) ECOG performance status 0 44 (32) 37 (30) 1 81 (59) 74 (61)”